ALNY logo

Alnylam Pharmaceuticals (ALNY) Depreciation And Amortization

Annual D&A

$56.67 M
+$2.62 M+4.84%

December 31, 2024

Summary

Performance

1-Year Change

+4.84%

3-Year Change

-36.82%

5-Year Change

+4.23%

15-Year Change

+376.3%

ALNY Depreciation And Amortization Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

86.53%
ALNY annual depreciation & amortization is higher than 86.53% of companies in Healthcare sector

High & Low

All-time High

$89.69 M
ALNY annual depreciation & amortization is currently -36.82% below its historical high of $89.69 million

3-Year Low

$44.47 M
ALNY annual depreciation & amortization is currently +27.44% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
ALNY previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
ALNY next annual earnings announcement has not yet been scheduled

Related metrics

Annual Total Expenses

$2.43 B
ALNY annual total expenses is $2.43 billion

Annual Operating Expenses

$2.10 B
ALNY annual total operating expenses is $2.10 billion

Annual Cost Of Goods Sold

$323.37 M
ALNY annual cost of goods sold is $323.37 million

Annual Interest Expense

$141.86 M
ALNY annual interest expense is $141.86 million

Quarterly D&A

-$20.55 M
-$47.58 M-175.99%

December 31, 2024

Summary

Performance

3-Month Change

-175.99%

1-Year Change

-8.11%

3-Year Change

-8.11%

5-Year Change

-8.11%

ALNY Quarterly D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

0.74%
ALNY quarterly depreciation & amortization is higher than 0.74% of companies in Healthcare sector

High & Low

All-time High

$32.42 M
ALNY quarterly depreciation & amortization is currently -163.37% below its historical high of $32.42 million

3-Year Low

-$20.55 M
ALNY quarterly depreciation & amortization is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ALNY previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ALNY next earnings announcement is scheduled for May 2, 2025

Related metrics

Quarterly Total Expenses

$698.33 M
ALNY quarterly total expenses is $698.33 million

Quarterly Operating Expenses

$595.51 M
ALNY quarterly total operating expenses is $595.51 million

Quarterly Cost Of Goods Sold

$102.82 M
ALNY quarterly cost of goods sold is $102.82 million

Quarterly Interest Expense

$38.97 M
ALNY quarterly interest expense is $38.97 million

TTM D&A

$56.67 M
-$1.54 M-2.65%

December 31, 2024

Summary

Performance

3-Month Change

-2.65%

1-Year Change

+4.84%

3-Year Change

+4.84%

5-Year Change

+4.84%

ALNY TTM D&A Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

86.82%
ALNY TTM depreciation & amortization is higher than 86.82% of companies in Healthcare sector

High & Low

All-time High

$96.87 M
ALNY TTM depreciation & amortization is currently -41.50% below its historical high of $96.87 million

3-Year Low

$44.47 M
ALNY TTM depreciation & amortization is currently +27.44% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
ALNY previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 2, 2025
ALNY next earnings announcement is scheduled for May 2, 2025

Related metrics

Annual Total Expenses

$2.43 B
ALNY annual total expenses is $2.43 billion

Annual Operating Expenses

$2.10 B
ALNY annual total operating expenses is $2.10 billion

TTM Cost Of Goods Sold

$323.37 M
ALNY TTM cost of goods sold is $323.37 million

TTM Interest Expense

$141.86 M
ALNY TTM interest expense is $141.86 million

ALNY Depreciation And Amortization Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+4.8%-8.1%+4.8%
3 y3 years-36.8%-8.1%+4.8%
5 y5 years+4.2%-8.1%+4.8%

ALNY Depreciation And Amortization Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-36.8%+27.4%-176.0%at low-41.5%+27.4%
5 y5-year-36.8%+27.4%-163.4%at low-41.5%+27.4%
alltimeall time-36.8%>+9999.0%-163.4%at low-41.5%>+9999.0%

Alnylam Pharmaceuticals Depreciation And Amortization History

DateAnnualQuarterlyTTM
Dec 2024
$56.67 M(+4.8%)
-$20.55 M(-176.0%)
$56.67 M(-2.6%)
Sep 2024
-
$27.04 M(+9.5%)
$58.21 M(+6.4%)
Jun 2024
-
$24.69 M(-3.1%)
$54.71 M(+2.3%)
Mar 2024
-
$25.49 M(-234.1%)
$53.46 M(-1.1%)
Dec 2023
$54.05 M(+21.6%)
-$19.00 M(-180.8%)
$54.05 M(-4.9%)
Sep 2023
-
$23.53 M(+0.4%)
$56.86 M(+5.3%)
Jun 2023
-
$23.45 M(-10.1%)
$53.98 M(+6.3%)
Mar 2023
-
$26.08 M(-261.0%)
$50.77 M(+14.2%)
Dec 2022
$44.47 M(-50.4%)
-$16.20 M(-178.4%)
$44.47 M(-45.8%)
Sep 2022
-
$20.65 M(+2.0%)
$82.12 M(-3.0%)
Jun 2022
-
$20.24 M(+2.3%)
$84.69 M(-12.6%)
Mar 2022
-
$19.78 M(-7.8%)
$96.87 M(+8.0%)
Dec 2021
$89.69 M(+20.5%)
$21.45 M(-7.6%)
$89.69 M(+0.6%)
Sep 2021
-
$23.22 M(-28.4%)
$89.12 M(+5.3%)
Jun 2021
-
$32.42 M(+157.3%)
$84.67 M(+20.9%)
Mar 2021
-
$12.60 M(-39.7%)
$70.03 M(-5.9%)
Dec 2020
$74.44 M(+36.9%)
$20.88 M(+11.2%)
$74.44 M(+9.0%)
Sep 2020
-
$18.77 M(+5.6%)
$68.32 M(+8.7%)
Jun 2020
-
$17.78 M(+4.5%)
$62.87 M(+9.8%)
Mar 2020
-
$17.01 M(+15.2%)
$57.28 M(+5.4%)
Dec 2019
$54.37 M(+256.6%)
$14.76 M(+10.8%)
$54.37 M(+10.9%)
Sep 2019
-
$13.33 M(+9.4%)
$49.03 M(+35.8%)
Jun 2019
-
$12.19 M(-13.5%)
$36.11 M(+38.0%)
Mar 2019
-
$14.09 M(+49.5%)
$26.16 M(+71.6%)
Dec 2018
$15.25 M(+28.2%)
$9.43 M(+2227.4%)
$15.25 M(+89.0%)
Sep 2018
-
$405.00 K(-81.9%)
$8.07 M(-28.3%)
Jun 2018
-
$2.24 M(-29.5%)
$11.25 M(-6.8%)
Mar 2018
-
$3.18 M(+41.6%)
$12.08 M(+1.5%)
Dec 2017
$11.90 M(-21.4%)
$2.25 M(-37.4%)
$11.90 M(-6.1%)
Sep 2017
-
$3.59 M(+17.0%)
$12.67 M(+0.7%)
Jun 2017
-
$3.07 M(+2.2%)
$12.58 M(-7.0%)
Mar 2017
-
$3.00 M(-0.6%)
$13.53 M(-10.6%)
Dec 2016
$15.13 M(-20.6%)
$3.02 M(-13.8%)
$15.13 M(-11.9%)
Sep 2016
-
$3.50 M(-12.7%)
$17.18 M(-9.3%)
Jun 2016
-
$4.01 M(-12.8%)
$18.95 M(-5.1%)
Mar 2016
-
$4.60 M(-9.2%)
$19.96 M(+4.8%)
Dec 2015
$19.05 M(+59.7%)
$5.07 M(-3.8%)
$19.05 M(+10.0%)
Sep 2015
-
$5.27 M(+5.0%)
$17.32 M(+14.2%)
Jun 2015
-
$5.02 M(+36.1%)
$15.17 M(+16.5%)
Mar 2015
-
$3.69 M(+10.4%)
$13.02 M(+9.1%)
Dec 2014
$11.93 M
$3.34 M(+7.2%)
$11.93 M(+6.4%)
Sep 2014
-
$3.12 M(+8.7%)
$11.21 M(+3.3%)
Jun 2014
-
$2.87 M(+10.3%)
$10.86 M(+1.5%)
DateAnnualQuarterlyTTM
Mar 2014
-
$2.60 M(-1.0%)
$10.70 M(+4.6%)
Dec 2013
$10.23 M(+13.2%)
$2.63 M(-5.0%)
$10.23 M(+6.3%)
Sep 2013
-
$2.76 M(+2.0%)
$9.63 M(+5.2%)
Jun 2013
-
$2.71 M(+27.5%)
$9.15 M(+1.2%)
Mar 2013
-
$2.13 M(+5.1%)
$9.04 M(+0.1%)
Dec 2012
$9.04 M(+76.3%)
$2.02 M(-11.4%)
$9.04 M(+9.5%)
Sep 2012
-
$2.29 M(-12.3%)
$8.25 M(+14.2%)
Jun 2012
-
$2.60 M(+22.8%)
$7.22 M(+22.3%)
Mar 2012
-
$2.12 M(+71.5%)
$5.91 M(+15.3%)
Dec 2011
$5.13 M(+3.7%)
$1.24 M(-2.0%)
$5.13 M(-1.0%)
Sep 2011
-
$1.26 M(-1.9%)
$5.18 M(-0.1%)
Jun 2011
-
$1.29 M(-3.9%)
$5.18 M(+1.3%)
Mar 2011
-
$1.34 M(+3.7%)
$5.12 M(+3.6%)
Dec 2010
$4.94 M(-17.5%)
$1.29 M(+2.0%)
$4.94 M(+3.2%)
Sep 2010
-
$1.27 M(+3.5%)
$4.79 M(+3.3%)
Jun 2010
-
$1.22 M(+5.3%)
$4.63 M(-13.5%)
Mar 2010
-
$1.16 M(+2.2%)
$5.35 M(-10.7%)
Dec 2009
$5.99 M(+4.6%)
$1.14 M(+2.3%)
$5.99 M(-9.9%)
Sep 2009
-
$1.11 M(-42.8%)
$6.65 M(-7.2%)
Jun 2009
-
$1.94 M(+7.8%)
$7.17 M(+9.1%)
Mar 2009
-
$1.80 M(+0.2%)
$6.58 M(+14.9%)
Dec 2008
$5.73 M(+40.3%)
$1.80 M(+10.2%)
$5.73 M(+18.6%)
Sep 2008
-
$1.63 M(+21.2%)
$4.83 M(+13.7%)
Jun 2008
-
$1.35 M(+41.5%)
$4.25 M(+10.7%)
Mar 2008
-
$951.00 K(+5.4%)
$3.84 M(-6.0%)
Dec 2007
$4.08 M(+7.0%)
$902.00 K(-13.9%)
$4.08 M(-4.3%)
Sep 2007
-
$1.05 M(+11.8%)
$4.27 M(-15.8%)
Jun 2007
-
$937.00 K(-21.6%)
$5.07 M(+20.1%)
Mar 2007
-
$1.20 M(+9.9%)
$4.22 M(+10.6%)
Dec 2006
$3.81 M(+22.3%)
$1.09 M(-41.3%)
$3.81 M(+9.6%)
Sep 2006
-
$1.85 M(+2003.4%)
$3.48 M(+46.9%)
Jun 2006
-
$88.00 K(-88.8%)
$2.37 M(-26.7%)
Mar 2006
-
$789.00 K(+4.9%)
$3.23 M(+3.7%)
Dec 2005
$3.12 M(+27.6%)
$752.00 K(+1.6%)
$3.12 M(+0.0%)
Sep 2005
-
$740.00 K(-22.3%)
$3.12 M(+0.4%)
Jun 2005
-
$952.00 K(+41.0%)
$3.11 M(+19.1%)
Mar 2005
-
$675.00 K(-10.1%)
$2.61 M(+6.7%)
Dec 2004
$2.44 M(+191.6%)
$751.00 K(+3.2%)
$2.44 M(+44.4%)
Sep 2004
-
$728.00 K(+60.4%)
$1.69 M(+75.4%)
Jun 2004
-
$454.00 K(-11.2%)
$965.00 K(+88.8%)
Mar 2004
-
$511.00 K
$511.00 K
Dec 2003
$838.00 K(+2227.8%)
-
-
Dec 2002
$36.00 K
-
-

FAQ

  • What is Alnylam Pharmaceuticals annual depreciation & amortization?
  • What is the all time high annual D&A for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals annual D&A year-on-year change?
  • What is Alnylam Pharmaceuticals quarterly depreciation & amortization?
  • What is the all time high quarterly D&A for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals quarterly D&A year-on-year change?
  • What is Alnylam Pharmaceuticals TTM depreciation & amortization?
  • What is the all time high TTM D&A for Alnylam Pharmaceuticals?
  • What is Alnylam Pharmaceuticals TTM D&A year-on-year change?

What is Alnylam Pharmaceuticals annual depreciation & amortization?

The current annual D&A of ALNY is $56.67 M

What is the all time high annual D&A for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high annual depreciation & amortization is $89.69 M

What is Alnylam Pharmaceuticals annual D&A year-on-year change?

Over the past year, ALNY annual depreciation & amortization has changed by +$2.62 M (+4.84%)

What is Alnylam Pharmaceuticals quarterly depreciation & amortization?

The current quarterly D&A of ALNY is -$20.55 M

What is the all time high quarterly D&A for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high quarterly depreciation & amortization is $32.42 M

What is Alnylam Pharmaceuticals quarterly D&A year-on-year change?

Over the past year, ALNY quarterly depreciation & amortization has changed by -$1.54 M (-8.11%)

What is Alnylam Pharmaceuticals TTM depreciation & amortization?

The current TTM D&A of ALNY is $56.67 M

What is the all time high TTM D&A for Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals all-time high TTM depreciation & amortization is $96.87 M

What is Alnylam Pharmaceuticals TTM D&A year-on-year change?

Over the past year, ALNY TTM depreciation & amortization has changed by +$2.62 M (+4.84%)